Thillainadesan J, Schlaphoff G, Gibson K A, Hassett G M, McNeil H P
South Western Sydney Clinical School, University of New South Wales, New South Wales, Australia.
J Med Imaging Radiat Oncol. 2010 Aug;54(4):307-14. doi: 10.1111/j.1754-9485.2010.02176.x.
This study aimed to determine outcomes of percutaneous vertebroplasty for osteoporotic vertebral compression fractures (VCFs).
Prospective assessment of short-term (<or=6 weeks), medium-term (6 months) and long-term (29 months) outcomes of vertebroplasty, followed by a retrospective long-term follow-up of patients treated with vertebroplasty compared with conservative therapy. Outcomes measured were visual analogue scale pain scores, analgesic use, disability scores using the Roland Morris Disability questionnaire and a number of new VCFs.
In 27 patients with acute VCFs followed prospectively, vertebroplasty resulted in significant reductions in pain levels (56-mm reduction on a 100-mm scale) and disability scores (11.8-point reduction on a 24-point scale) at all follow-up points up to a mean of 29 months compared with pre-vertebroplasty levels (P < 0.001). Analgesic use was significantly less intense in the short and medium term after vertebroplasty (P < 0.005). In 25 patients who had vertebroplasty for VCF, a sustained reduction in all outcomes was demonstrated at a mean follow-up of 30 months, with less pain, significantly lower disability scores (P < 0.05) and less analgesic use (P < 0.05) compared with nine conservatively treated subjects. During the follow-up period, six new VCFs occurred in 4/25 vertebroplasty patients compared with four new VCFs in 2/9 control subjects.
Vertebroplasty provides significant and clinically meaningful reductions in pain, analgesic use, and disability in the short, medium and long term. Compared with conservative therapy, vertebroplasty provides significantly greater functional improvement and reduction in analgesic use. The procedure is relatively safe with no clearly increased risk of new vertebral fractures.
本研究旨在确定经皮椎体成形术治疗骨质疏松性椎体压缩骨折(VCF)的效果。
对椎体成形术的短期(≤6周)、中期(6个月)和长期(29个月)效果进行前瞻性评估,随后对接受椎体成形术治疗的患者与保守治疗患者进行回顾性长期随访。测量的结果包括视觉模拟量表疼痛评分、镇痛药使用情况、使用罗兰·莫里斯残疾问卷的残疾评分以及新发生的VCF数量。
在27例急性VCF患者的前瞻性随访中,与椎体成形术前水平相比,椎体成形术在平均29个月的所有随访点均导致疼痛水平显著降低(100毫米量表上降低56毫米)和残疾评分显著降低(24分制量表上降低11.8分)(P<0.001)。椎体成形术后短期和中期镇痛药使用强度显著降低(P<0.005)。在25例接受VCF椎体成形术的患者中,平均随访30个月时所有结果均持续降低,与9例保守治疗的患者相比,疼痛减轻、残疾评分显著更低(P<0.05)且镇痛药使用更少(P<0.05)。在随访期间,25例椎体成形术患者中有4例发生6例新的VCF,而9例对照患者中有2例发生4例新的VCF。
椎体成形术在短期、中期和长期均能显著且具有临床意义地减轻疼痛、减少镇痛药使用并降低残疾程度。与保守治疗相比,椎体成形术能显著改善功能并减少镇痛药使用。该手术相对安全,新椎体骨折风险无明显增加。